Type 5 Diabetes — The WHO/IDF Consensus

Presentation

This landmark consensus, published in The Lancet Global Health in 2025, addressed a clinical reality that South Asian physicians have observed for decades: young, lean patients presenting with diabetes that doesn't fit the Type 1 or Type 2 classification. These patients have profound beta-cell secretory failure but normal insulin sensitivity — they don't have autoimmune destruction, they're not obese, and they don't have ketoacidosis.

Key Finding

Type 5 Diabetes is defined by: BMI <18.5 kg/m², age <30 at onset, history of undernutrition from birth, substantial impairment of insulin secretion with normal insulin sensitivity, no islet autoantibodies, and no ketoacidosis tendency. The consensus meeting was held in Vellore, India in January 2025, reflecting that this is overwhelmingly a South Asian and Sub-Saharan African condition.

Intervention & Outcome

No specific intervention was defined by the consensus. The classification itself is the intervention — it creates a diagnostic category that prevents these patients from being misclassified as Type 1 (leading to unnecessary insulin therapy from day one) or Type 2 (leading to metformin therapy that doesn't address their primary problem of beta-cell insufficiency).

First Principles

Beta-cell mass is set during fetal and early childhood development. Maternal undernutrition limits the population of beta cells the pancreas ever generates. These individuals enter adulthood with a smaller insulin-producing reserve. They tolerate baseline metabolic loads but decompensate under any additional stress (modest weight gain, infection, pregnancy, steroids). The mechanism is developmental, not autoimmune or insulin-resistance-driven.